Half-Year Report Reveals Strong Cash Position and Clinical Momentum, Bolstered by Dr. Reddy's Upfront Payment
IMMP has more than doubled off its 52-week low of $1.32 on light trading volume (0.2× avg).
Summary
Immutep's half-year report shows a pro-forma cash balance of A$129.3 million, significantly strengthened by a A$29.9 million upfront payment from Dr. Reddy's and a A$30 million vendor payment deferral, alongside continued positive clinical trial progress.
Key Events · Financing and Capital Events · IMMP
-
Significant Cash Injection from Dr. Reddy's Collaboration
The company reported a pro-forma cash and short-term investments balance of A$129.3 million as of December 31, 2025, following the receipt of a A$29.9 million (USD 20 million) upfront payment from Dr. Reddy's in January 2026. This payment was previously announced on January 30, 2026, and is now reflected in the financial report.
-
Vendor Payment Deferral Boosts Liquidity
A long-term vendor agreed to defer approximately A$30 million in payments for future Biologics License Application (BLA) readiness services by up to 30 months, further strengthening the company's cash runway.
-
Increased R&D Expenses Drive Higher Net Loss
The net loss for the half-year ended December 31, 2025, increased to A$44.86 million, primarily due to a A$21.3 million increase in R&D and intellectual property expenses as clinical trial activities for eftilagimod alfa and IMP761 advanced.
-
Positive Clinical Trial Progress Across Multiple Programs
The report detailed ongoing progress in the pivotal TACTI-004 Phase III trial (50% patient enrollment achieved by early February 2026, futility analysis on track for Q1 CY2026), positive FDA feedback for TACTI-003 (HNSCC) and AIPAC-003 (MBC), and promising data from EFTISARC-NEO (STS) and INSIGHT-003 (NSCLC).
Analysis · IMMP · Life Sciences
Immutep's half-year financial report highlights a significantly strengthened balance sheet, primarily driven by the A$29.9 million upfront payment from the Dr. Reddy's collaboration, which was received in January 2026. This payment, representing approximately 7.3% of the company's market capitalization, substantially boosts the pro-forma cash balance to A$129.3 million and extends the company's operational runway. Further enhancing liquidity, a long-term vendor agreed to defer A$30 million in payments for future services. While the company reported an increased net loss due to higher R&D expenses, this is a typical and expected outcome for a clinical-stage biotech advancing multiple programs. The report also provides comprehensive updates on positive clinical trial progress across several indications, including favorable FDA feedback for TACTI-003 and AIPAC-003, and promising data from EFTISARC-NEO and INSIGHT-003. This combination of robust financing and continued clinical advancement positions Immutep favorably for upcoming milestones.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMP was trading at $2.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $409.2M. The 52-week trading range was $1.32 to $3.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.